(Health-NewsWire.Net, October 21, 2020 ) The Apheresis Procedure Market is primarily driven by the rising prevalence of chronic diseases and the growing number of trauma and injury cases, the increasing demand for source plasma from biopharmaceutical companies, the rising demand for blood components and growing concerns regarding blood safety, the increase in the number of complex surgical procedures, and the favorable reimbursement for apheresis procedures.
The global apheresis market is expected to reach USD 2.7 billion by 2025 from an estimated value of USD 1.7 billion in 2019, growing at a CAGR of 8.1% during the forecast period.
However, the high cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through the rental model, fewer blood donations using apheresis due to lack of awareness, and the stringent donor recruitment criteria are factors expected to limit market growth to a certain extent in the coming years.
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950
Key Players:
The key players of Apheresis Procedure Market focus on increasing their market presence with the adoption of both organic and inorganic growth strategies. These include product launches, agreements, partnerships, collaborations, and acquisitions.
The prominent players in apheresis market are Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co. Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (Ireland), Medicap Clinic GmbH (Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed (Switzerland), Cytosorbents Corporation (US), and Toray Medical Co. Ltd. (Japan), among other key players.
Haemonetics Corporation (US) Haemonetics Corporation is a key competitor in the apheresis market for both the collection of cells and therapeutic apheresis. The company has a strong product profile in automated blood component collection. Haemonetics also has a wide geographic presence across the US, Europe, Japan, and Asia, which enables it to cater to its customers across the globe. Around 62% of the company’s revenue is generated from the US market. Haemonetics also focuses on high-growth emerging countries in order to increase its share in the apheresis market.
Fresenius SE & Co. KGaA (Germany) Fresenius is a global player in the Apheresis Procedure Market, with wide geographic coverage. The company has maintained its leading position in the market through its strong distribution networks across the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa.
Terumo BCT, Inc. (US) was the leading player in the apheresis market and accounted for the largest share in 2018. The company is known for its diversified product offerings in the field of apheresis. Terumo’s products include the Spectra Optia, COBE Spectra, and Trima Accel, and these are widely adopted by blood centers, blood component providers, hospitals, and transfusion centers for donor & therapeutic apheresis purposes. The company has a significant global footprint owing to its strong sales and distribution network.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=950
Geographical Growth:
North America accounted for the largest market share in 2018
North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com
|